Pediatric Infectious Disease

Register      Login

VOLUME 3 , ISSUE 1 ( January-March, 2021 ) > List of Articles

Original Article

Candidemia in a Pediatric Population: A 10-year Indian Study

Ranjeeta Adhikary, Bhavana Malavalli Venkatesh, Sangeeta Joshi, Anjana Aravinda

Keywords : Candidemia, Children, Invasive candidiasis

Citation Information : Adhikary R, Venkatesh BM, Joshi S, Aravinda A. Candidemia in a Pediatric Population: A 10-year Indian Study. Pediatr Inf Dis 2021; 3 (1):1-8.

DOI: 10.5005/jp-journals-10081-1255

License: CC BY-NC 4.0

Published Online: 01-03-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction: Candidemia has emerged as one of the life-threatening causes of invasive infection in both adults and children worldwide. Materials and methods: We performed a retrospective study of children (≤16 years) with candidemia diagnosed in our center in 2010 to 2019. Demographics, comorbidities, Candida species distribution, antifungal susceptibility, and outcomes were analyzed. Results: A total of 96 children were identified in the last 10 years. The predominant species identified were C. tropicalis (23%), C. parapsilosis (15.6%), C. pelliculosa (15.6%), C. albicans (13.6%), C. krusei (7.3%), and C. haemulonii (5.2%). Male to female ratio was 2:1. The most common risk factor was found to be congenital malformations (27%), followed by hematological malignancy in 13.5%. Candidemia was diagnosed while being admitted in the intensive care unit in 74%, 14.5% in wards, and 11.5% in outpatients. The overall mortality rate was found to be 31.3%. C. tropicalis was found to be sensitive to fluconazole in 95.5%, flucytocine in 95.2%, and 100% susceptible to amphotericin B, voriconazole, and caspofungin. Conclusion: Invasive candidiasis occurs frequently in hospitalized patients and is associated with high mortality rates. C. tropicalis was the most frequently isolated species. We have observed a shift in Candida spp. with an increasing isolation of C. pelliculosa. The occurrence of azole resistance is a matter of concern. Clinical significance: This type of data analysis is needed to track trends of serious infection and to develop guidelines for infection control strategies and antimicrobial stewardship program.


PDF Share
  1. Toda M, Williams SR, Berkow EL, et al. Population-based active surveillance for culture-confirmed candidemia - four sites, United States, 2012-2016. MMWR Surveill Summ 2019;68(8):1–15. DOI: 10.15585/mmwr.ss6808a1.
  2. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34(1):1–14. DOI: 10.1086/668770.
  3. Steinbach WJ. Pediatric invasive candidiasis: epidemiology and diagnosis in children. J Fungi (Basel) 2016;2(1):5. DOI: 10.3390/jof2010005.
  4. Kalkanci A, Dizbay M, Turan O, et al. Nosocomial transmission of Candida pelliculosa fungemia in a pediatric intensive care unit and review of the literature. Turk J Pediatr 2010;52(1):42–49.
  5. Taylor G, Buchanan-Chell M, Kirkland T, et al. Long term trends in the occurrence of nosocomial blood stream infection. Can J Infect Dis 2000;11(1):29–33. DOI: 10.1155/2000/393194.
  6. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20(1):133–163. DOI: 10.1128/CMR.00029-06.
  7. Aslan N, Yildizdas D, Alabaz D, et al. Invasive Candida infections in a pediatric intensive care unit in Turkey: evaluation of an 11-year period. J Pediatr Intensive Care 2020;9(1):21–26. DOI: 10.1055/s-0039-1695061.
  8. Dadar M, Tiwari R, Karthik K, et al. Candida albicans - biology, molecular characterization, pathogenicity, and advances in diagnosis and control - an update. Microb Pathog 2018;117:128–138. DOI: 10.1016/j.micpath.2018.02.028.
  9. Rajendran R, Sherry L, Deshpande A, et al. A prospective surveillance study of candidaemia: epidemiology, risk factors, antifungal treatment and outcome in hospitalized patients. Front Microbiol 2016;7:915. DOI: 10.3389/fmicb.2016.00915.
  10. Alkharashi N, Aljohani S, Layqah L, et al. Candida bloodstream infection: changing pattern of occurrence and antifungal susceptibility over 10 Years in a tertiary care Saudi hospital. Can J Infect Dis Med Microbiol 2019;2019:2015692. DOI: 10.1155/2019/2015692.
  11. Puig-Asensio M, Ruiz-Camps I, Fernández-Ruiz M, et al. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. Clin Microbiol Infect 2015;21(5). DOI: 10.1016/j.cmi.2014.12.027.
  12. Omrani AS, Makkawy EA, Baig K, et al. Ten-year review of invasive Candida infections in a tertiary care center in Saudi Arabia. Saudi Med J 2014;35(8):821–826.
  13. Lyon GM, Karatela S, Sunay S, et al. Candida surveillance study investigators. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol 2010;48(4):1270–1275. DOI: 10.1128/JCM.02363-09.
  14. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. J Clin Microbiol 2013;51(3):841–848. DOI: 10.1128/JCM.02566-12.
  15. Otag F, Yarpuzlu M, Gulbudak H, et al. Candida pelliculosa fungemia cases in pediatric intensive care unit. Pediatr Inf 2015;9(2):85–90. DOI: 10.5152/ced.2015.1662.
  16. Chatterjee S, Alampalli SV, Nageshan RK, et al. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics 2015;16(1):686. DOI: 10.1186/s12864-015-1863-z.
  17. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts—Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
  18. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs for antifungal agents, version 10.0, 2020. http://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals/.
  19. Jung SI, Shin JH, Choi HJ, et al. Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea. Ann Lab Med 2012;32(6):426–428. DOI: 10.3343/alm.2012.32.6.426.
  20. Wattal C, Goel N. Pediatric blood cultures and antibiotic resistance: an overview. Indian J Pediatr 2020;87(2):125–131. DOI: 10.1007/s12098-019-03123-y.
  21. Kaur R, Jaggi S, Dhakad MS, et al. An etiological and antifungal profile of candidemia in children. Int J Community Med Public Health 2019;6(9):3899–3904. DOI: 10.18203/2394-6040.ijcmph20193990.
  22. Tak V, Mathur P, Varghese P, et al. The epidemiological profile of candidemia at an Indian trauma care center. J Lab Physicians 2014;6(2):96–101. DOI: 10.4103/0974-2727.141506.
  23. Gonzalez GM, Trevino-Rangel RJ, Palma-Nicolas JP, et al. Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study. J Antimicrob Chemother 2013;68(12):2847–2851. DOI: 10.1093/jac/dkt283.
  24. Singh R, Parija SC. Candida parapsilosis: an emerging fungal pathogen. Indian J Med Res 2012;136(4):671–673.
  25. Warris A. Candida auris, what do paediatricians need to know? Arch Dis Child 2018;103(9):891–894. DOI: 10.1136/archdischild-2017-313960.
  26. Rodrigues LS, Motta FA, Picharski GL, et al. Invasive candidiasis: risk factor for mortality in a pediatric tertiary care hospital in south of Brazil. Medicine (Baltimore) 2019;98(23):e15933. DOI: 10.1097/MD.0000000000015933.
  27. Charsizadeh A, Mirhendi H, Nikmanesh B, et al. Candidemia in children caused by uncommon species of Candida. Arch Pediatr Infect Dis 2018;6(2):e11895. DOI: 10.5812/pedinfect.11895.
  28. Tragiannidis A, Fegeler W, Rellensmann G, et al. Candidaemia in a European paediatric university hospital: a 10-year observational study. Clin Microbiol Infect 2012;18(2):E27–E30. DOI: 10.1111/j.1469-0691.2011.03720.x.
  29. Lin HC, Lin HY, Su BH, et al. Reporting an outbreak of Candida pelliculosa fungemia in a neonatal intensive care unit. J Microbiol Immunol Infect 2013;46(6):456–462. DOI: 10.1016/j.jmii.2012.07.013.
  30. Krcmery V, Kisac P, Liskova A. Voriconazole and posaconazole resistant Candida pelliculosa fungemia after cardiac surgery. Pediatr Infect Dis J 2009;28(1):75–76. DOI: 10.1097/INF.0b013e31818edde1.
  31. Santolaya ME, Thompson L, Benadof D, et al. A prospective, multi-center study of Candida bloodstream infections in Chile. PLoS ONE 2019;14(3):e0212924. DOI: 10.1371/journal.pone.0212924.
  32. Dutta A, Palazzi DL. Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J 2011;30(8):664–668. DOI: 10.1097/INF.0b013e318213da0f.
  33. Lausch KR, Schultz Dungu KH, Callesen MT, et al. Pediatric candidemia epidemiology and morbidities: a nationwide cohort. Pediatr Infect Dis J 2019;38(5):464–469. DOI: 10.1097/INF.0000000000002207.
  34. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37(5):634–643. DOI: 10.1086/376906.
  35. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309–317. DOI: 10.1086/421946.
  36. Al-Dorzi HM, Sakkijha H, Khan R, et al. Invasive candidiasis in critically ill patients: a prospective cohort study in two tertiary care centers. J Intensive Care Med 2018(6):885066618767835. DOI: 10.1177/0885066618767835.
  37. Adhikary R, Joshi S. Species distribution and anti-fungal susceptibility of Candidaemia at a multi super-specialty center in Southern India. Indian J Med Microbiol 2011;29(3):309–311. DOI: 10.4103/0255-0857.83920.
  38. Badiee P, Alborzi A. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: a five year study. Iran J Microbiol 2011;3(4):183–188.
  39. Kothavade RJ, Kura MM, Valand AG, et al. Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole. J Med Microbiol 2010;59(Pt 8):873–880. DOI: 10.1099/jmm.0.013227-0.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.